Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 2/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735625 | 1.00 | NR4A1 (0.76) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL13856167 | 0.86 | NR4A1 (1.00) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL3755954 | 0.79 | ITGA4 (0.65) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL3755958 | 0.79 | ITGA4 (0.65) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL3757779 | 0.78 | NR4A1 (0.64) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL3757780 | 0.78 | NR4A1 (0.64) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL5734258 | 0.78 | ABL1 (0.64) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL5734261 | 0.78 | ABL1 (0.64) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL5735693 | 0.77 | NR4A1 (0.63) | NR4A1POLBMEN1KMT2AMAPT | |
| SCHEMBL5735689 | 0.77 | NR4A1 (0.63) | NR4A1POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014120683-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-08-07 | — | — | WO | claimed |
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | claimed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | claimed |
| US-9951024-B2 | Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170349553-A1 | SMALL- MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | UNIVERSITY OF CINCINNATI | 2017-12-07 | — | — | US | disclosed |
| US-20160083353-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| WO-2014120683-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | disclosed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083353-A1 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | ARHGEF1, ARHGEF2, ARHGDIB | NR4A1 4748/4885POLB 3873/4885MEN1 2743/4885 |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | G6PC1, PPM1D, PTPRS | NR4A1 2744/4885POLB 4641/4885MEN1 3799/4885 |
| US-20170349553-A1 | SMALL- MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS | ARHGEF1, ARHGEF2, ARHGDIB | NR4A1 4748/4885POLB 3873/4885MEN1 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.